Exubera Related Published Studies
Well-designed clinical trials related to Exubera (Insulin Inhalation)
Population pharmacokinetic model of human insulin following different routes of administration. [2011.07]
Prandial inhaled insulin plus basal insulin glargine versus twice daily biaspart insulin for type 2 diabetes: a multicentre randomised trial. [2010.06.26]
The contribution of pretreatment expectations and expectation-perception difference to change in treatment satisfaction and end point treatment satisfaction in the context of initiation of inhaled insulin therapy in patients with type 2 diabetes. [2010.06]
Expectations about and experiences with insulin therapy contribute to diabetes treatment satisfaction in insulin-naive patients with type 2 diabetes. [2010.06]
Psychometric properties of an instrument for assessing the experience of patients treated with inhaled insulin: the inhaled insulin treatment questionnaire (IITQ). [2010.03.24]
Titration of inhaled human insulin (Exubera) in a treat-to-target regimen for patients with type 2 diabetes. [2010.03]
The effect of terbutaline on the absorption of pulmonary administered insulin in subjects with asthma. [2010.03]
Glycemic control with preprandial versus basal insulin in patients with type 2 diabetes mellitus poorly controlled by oral antidiabetes agents. [2010.02]
Effect of technosphere inhaled insulin on quality of life and treatment satisfaction. [2010.01]
Safety and efficacy of inhaled human insulin (exubera) during discontinuation and readministration of therapy in adults with type 2 diabetes: a 3-year randomized controlled trial. [2009.11]
Inspiratory efforts achieved in use of the Technosphere insulin inhalation system. [2009.09.01]
AIR insulin capsules of different dose strengths may be combined to yield equivalent pharmacokinetics and glucodynamics. [2009.09]
Comparison of prandial AIR inhaled insulin alone to intensified insulin glargine alone and to AIR insulin plus intensified insulin glargine in patients with type 2 diabetes previously treated with once-daily insulin glargine. [2009.09]
A comparison between simplified and intensive dose-titration algorithms using AIR inhaled insulin for insulin-naive patients with type 2 diabetes in a randomized noninferiority trial. [2009.09]
Two-year efficacy and safety of AIR inhaled insulin in patients with type 1 diabetes: An open-label randomized controlled trial. [2009.09]
Does availability of AIR insulin increase insulin use and improve glycemic control in patients with type 2 diabetes? [2009.09]
Safety and efficacy of AIR inhaled insulin compared with subcutaneous insulin in patients having diabetes and asthma: A 12-month, randomized, noninferiority trial. [2009.09]
Initiation of prandial insulin therapy with AIR inhaled insulin or insulin lispro in patients with type 2 diabetes: A randomized noninferiority trial. [2009.09]
Efficacy and safety of AIR inhaled insulin compared to insulin lispro in patients with type 1 diabetes mellitus in a 6-month, randomized, noninferiority trial. [2009.09]
Pharmacokinetics and linear exposure of AFRESA compared with the subcutaneous injection of regular human insulin. [2009.07]
A randomized clinical trial comparing the effect of basal insulin and inhaled mealtime insulin on glucose variability and oxidative stress. [2009.07]
Glycemic exposure is affected favorably by inhaled human insulin (Exubera) as compared with subcutaneous insulin glargine (Lantus) in patients with type 2 diabetes. [2009.05]
PROMAXX inhaled insulin: safe and efficacious administration with a commercially available dry powder inhaler. [2009.05]
Safety and efficacy of inhaled insulin (AERx iDMS) compared with subcutaneous insulin therapy in patients with Type 1 diabetes: 1-year data from a randomized, parallel group trial. [2009.03]
Time-action profile and patient assessment of inhaled insulin via the Exubera device in comparison with subcutaneously injected insulin aspart via the FlexPen device. [2009.02]
Safety and efficacy of inhaled human insulin (Exubera) during discontinuation and readministration of therapy in adults with type 1 diabetes: A 3-year randomized controlled trial. [2008.11]
Efficacy and safety of Technosphere inhaled insulin compared with Technosphere powder placebo in insulin-naive type 2 diabetes suboptimally controlled with oral agents. [2008.11]
Safety and efficacy of inhaled human insulin (Exubera((R))) during discontinuation and readministration of therapy in adults with type 1 diabetes: A 3-year randomized controlled trial. [2008.09.26]
The effect of the availability of inhaled insulin on glycaemic control in patients with Type 2 diabetes failing on oral therapy: the evaluation of Exubera as a therapeutic option on insulin initiation and improvement in glycaemic control in clinical practice (EXPERIENCE) trial. [2008.06]
Efficacy and safety of inhaled human insulin (Exubera) compared to subcutaneous insulin in children ages 6 to 11 years with type 1 diabetes mellitus: results of a 3-month, randomized, parallel trial. [2008.06]
AIR inhaled insulin versus subcutaneous insulin: pharmacokinetics, glucodynamics, and pulmonary function in asthma. [2008.04]
Effects of smoking cessation, acute re-exposure and nicotine replacement in smokers on AIR inhaled insulin pharmacokinetics and glucodynamics. [2008.04]
The effect of exercise on the absorption of inhaled human insulin in healthy volunteers. [2008.02]
Long-term tolerability of inhaled human insulin (Exubera) in patients with poorly controlled type 2 diabetes. [2007.10]
The effect of exercise on the absorption of inhaled human insulin via the AERx insulin diabetes management system in people with type 1 diabetes. [2007.10]
AIR inhaled insulin in subjects with chronic obstructive pulmonary disease: pharmacokinetics, glucodynamics, safety, and tolerability. [2007.07]
Randomized study to characterize glycemic control and short-term pulmonary function in patients with type 1 diabetes receiving inhaled human insulin (exubera). [2007.06]
A 6-month inhalation study to characterize the toxicity, pharmacokinetics, and pharmacodynamics of human insulin inhalation powder (HIIP) in beagle dogs. [2007.06]
Satisfaction and quality of life with premeal inhaled versus injected insulin in adolescents and adults with type 1 diabetes. [2007.06]
Two-year safety and efficacy of inhaled human insulin (Exubera) in adult patients with type 1 diabetes. [2007.03]
Effect of standard (self-directed) training versus intensive training for Lilly/Alkermes human insulin inhalation powder delivery system on patient-reported outcomes and patient evaluation of the system. [2007.02]
Comparison of standard (self-directed) versus intensive patient training for the human insulin inhalation powder (HIIP) delivery system in patients with type 2 diabetes: efficacy, safety, and training measures. [2007.02]
Effect of inhaled insulin on patient-reported outcomes and treatment preference in patients with type 1 diabetes. [2007.02]
Inhaled insulin as adjunctive therapy in subjects with type 2 diabetes failing oral agents: a controlled proof-of-concept study. [2006.09]
Will availability of inhaled human insulin (Exubera(R)) improve management of type 2 diabetes? The design of the Real World trial. [2006.08.10]
An open, randomized, parallel-group study to compare the efficacy and safety profile of inhaled human insulin (Exubera) with glibenclamide as adjunctive therapy in patients with type 2 diabetes poorly controlled on metformin. [2006.08]
Dissociation of lung function changes with humoral immunity during inhaled human insulin therapy. [2006.06.01]
An open, randomized, parallel-group study to compare the efficacy and safety profile of inhaled human insulin (Exubera) with metformin as adjunctive therapy in patients with type 2 diabetes poorly controlled on a sulfonylurea. [2006.06]
Smoking enhances absorption of insulin but reduces glucodynamic effects in individuals using the Lilly-Dura inhaled insulin system. [2006.05]
Efficacy and safety of preprandial human insulin inhalation powder versus injectable insulin in patients with type 1 diabetes. [2006.05]
Inhaled insulin improves glycemic control when substituted for or added to oral combination therapy in type 2 diabetes: a randomized, controlled trial. [2005.10.18]
The effect of insulin antibodies on the metabolic action of inhaled and subcutaneous insulin: a prospective randomized pharmacodynamic study. [2005.09]
Efficacy of inhaled insulin in patients with type 2 diabetes not controlled with diet and exercise: a 12-week, randomized, comparative trial. [2005.08]
Time-action profile of inhaled insulin in comparison with subcutaneously injected insulin lispro and regular human insulin. [2005.05]
Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 1 diabetes: results of a 6-month, randomized, comparative trial. [2004.11]
Efficacy and safety of inhaled insulin (exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes: results of a 6-month, randomized, comparative trial. [2004.10]
Well-designed clinical trials possibly related to Exubera (Insulin Inhalation)
Effect of the inhaled corticosteroid mometasone on small airway patency in patients with asthma. [2009.05]
Combination of recombinant human growth hormone and propranolol decreases hypermetabolism and inflammation in severely burned children. [2008.03]
Cardiac repolarization during hypoglycaemia and hypoxaemia in healthy males: impact of renin-angiotensin system activity. [2008.02]
A comparison of sevoflurane-fentanyl and neuroleptic anaesthesia for laparoscopic cholecystectomy of mildly obese patients. [2007.11]
Standardization of the single-breath diffusing capacity in a multicenter clinical trial. [2007.10]
Maximizing the value of validation findings to better understand treatment satisfaction issues for diabetes. [2007.08]
The comparative effects of sevoflurane versus isoflurane on cerebrovascular carbon dioxide reactivity in patients with diabetes mellitus. [2006.07]
Other research related to Exubera (Insulin Inhalation)
Pulmonary function over 2 years in diabetic patients treated with prandial
inhaled Technosphere Insulin or usual antidiabetes treatment: a randomized trial. [2012]
Pulmonary function over 2 years in diabetic patients treated with prandial inhaled Technosphere Insulin or usual antidiabetes treatment: a randomized trial. [2011.09.23]
Inhalative administration of insulin using a new bubble jet atomization device. [2011.06]
Novel hormonal delivery method using the ink-jet technology: application to pulmonary insulin therapies. [2011.05]
Factors associated with physician perceptions of and willingness to recommend inhaled insulin. [2011.02]
Patient-reported outcomes in adults with type 2 diabetes using mealtime inhaled
technosphere insulin and basal insulin versus premixed insulin. [2011]
Inhaled insulin: a model for pulmonary systemic absorption? [2010.10]
Successful treatment of severe subcutaneous insulin resistance with inhaled insulin therapy. [2010.09]
Technosphere insulin: an inhaled prandial insulin product. [2010.06]
New ways of insulin delivery. [2010.02]
Inhaled insulin-intrapulmonary, intranasal, and other routes of administration: mechanisms of action. [2010.01]
Titration of inhaled human insulin (Exubera) in a treat-to-target regimen for
patients with type 2 diabetes. [2010]
Prandial inhaled insulin plus basal insulin glargine versus twice daily biaspart
insulin for type 2 diabetes: a multicentre randomised trial. [2010]
The contribution of pretreatment expectations and expectation-perception
difference to change in treatment satisfaction and end point treatment
satisfaction in the context of initiation of inhaled insulin therapy in patients
with type 2 diabetes. [2010]
Psychometric properties of an instrument for assessing the experience of patients
treated with inhaled insulin: the inhaled insulin treatment questionnaire (IITQ). [2010]
Effect of technosphere inhaled insulin on quality of life and treatment
satisfaction. [2010]
Identifying factors that affect patients' willingness to pay for inhaled insulin. [2009.09]
Insulin-micro- and nanoparticles for pulmonary delivery. [2009.07.30]
Exubera inhaled insulin in patients with type 1 and type 2 diabetes: the first 12 months. [2009.07]
Inhaled insulin is associated with prolonged enhancement of glucose disposal in muscle and liver in the canine. [2009.03]
Inhaled insulin--does it become reality? [2008.12]
The role of inhaled insulin in the treatment of type 2 diabetes. [2008.11]
Two-year pulmonary safety and efficacy of inhaled human insulin (Exubera) in adult patients with type 2 diabetes. [2008.09]
Effects of inhaled human insulin on airway lining fluid composition in adults with diabetes. [2008.07]
Two-Year Pulmonary Safety and Efficacy of Inhaled Human Insulin (Exubera) in Adult Patients with Type 2 Diabetes. [2008.06.05]
Acute passive cigarette smoke exposure and inhaled human insulin (Exubera) pharmacokinetics. [2008.06]
[Inhaled insulin: a model for pulmonary systemic absorption?] [2008.02]
[Inhaled insulin. General characteristics. Repercussion on lung function] [2008.02]
Development of insulin delivery systems. [2008.01]
Preferences of patients with diabetes mellitus for inhaled versus injectable insulin regimens. [2008]
The new insulins. [2007.12]
Inhaled insulin. [2007.12]
[Inhaled insulin--the breakthrough in the treatment of diabetes?] [2007.09]
The clinical effectiveness and cost-effectiveness of inhaled insulin in diabetes mellitus: a systematic review and economic evaluation. [2007.09]
Evaluation of inhaled insulin therapy for diabetes mellitus. [2007.07]
Inhaled insulin: extending the horizons of inhalation therapy. [2007.07]
Inhaled human [rDNA origin] insulin, a novel formulation for diabetes mellitus. [2007.07]
Delivering needle-free insulin using AERx iDMS (insulin diabetes management system) technology. [2007.06]
|
